Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact IgG Fc binding region for optimal antibody-mediated anti-tumour activity.

Ociperlimab binds to TIGIT and blocks its interactions with the poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumour cells, resulting in activation of T cell mediated antitumor immune responses.

The Role of TIGIT

TIGIT, or T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain, is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T cells (Tregs), activated and exhausted T cells, and natural killer (NK) cells. TIGIT binds to two ligands, CD155 and CD112, expressed by tumour cells and antigen-presenting cells, which leads to inhibitory signalling in T cells and promotes functional exhaustion of tumour-infiltrating lymphocytes.

Tumour immune escape is a key mechanism of cancer progression whereby tumour cells can grow and metastasize by avoiding recognition and attack by the immune system. Targeting PD-1/PD-L1 pathway and additional immune inhibitory receptors expressed on T cells may overcome tumour immune escape and enhance anti-tumour response in patients with advanced solid tumours. In solid tumours, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.

Ociperlimab Clinical Trials

BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumours.

For more clinical trial information please visit CLINICALTRIALS.GOV.